Medicon Valley Alliance invites you to join this network meeting on Women in clinical trials

Women are underrepresented in clinical studies – especially in phase I trials were only 29 – 34 % of participants in Phase I trials are female. And 74 % of clinical trials do not report outcome by sex. But why is that?Is the reason for fewer women in clinical research mainly because researchers worry about the costs and legal issues if a participant gets pregnant? Also, does it seem like including women in studies brings extra expenses for sponsors because they might react differently to the new drugs, and age-related differences make things more complex? Does the tradition of leaving out certain groups affect how many women join clinical trials? And how do new rules about representation impact getting more women involved?Even though involving more women in trials can be more expensive and trickier for sponsors, it’s important. This helps us really understand how drugs work. If a drug has more problems or doesn’t work well in women, it can be even more expensive to take it off the market later. Including more women in studies gives us a better picture of how drugs work and how different groups might react to them.In this meeting we will hear from different experts, that will enlighten us on the EU regulatory perspective, the costs of including women, and on how to recruit more women.

SIGN UP»